China's RemeGen nets $100m led by Lilly Asia Ventures, Lake Bleu Capital

RemeGen's buildings for the development of antibody and biological agents. Source: RemeGen

Chinese biopharmaceutical firm RemeGen announced on Tuesday the completion of over $100 million in a new funding round jointly led China-based biomedical venture capital firm Lilly Asia Ventures, and Hong Kong’s healthcare investment fund Lake Bleu Capital.

Global healthcare investment firm Vivo Capital, Janchor Partners, a long-term industrialist investor led by John Ho in Hong Kong, New York-based investment manager Hudson Bay Capital, and OrbiMed, which manages $14 billion for healthcare investment, and existing investors participated in the new round.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter